Zoetis Inc. (ZTS) earnings on August 6, 2026
Prior outlook: Pessimistic Outcome: Partial
The stock rose 3.8% despite weak pet health demand and a downgrade, showing resilience after a volatile session.
ZTS price around the earnings
77.27
Change: +3.9%
2026-08-06, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Partial
- Thesis published
- Results released
Analysts maintain high upside targets despite recent price target cuts; Q1 was a miss. Trajectory collapsed into event.
Context analyzed before publication
- Trend
- Price trajectory collapsed significantly into the event, indicating an extreme selloff from prior positive trend strength.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2
- Analysts covering the stock
- 16
- Average price target
- 110.81
- Lowest price target
- 80
- Highest price target
- 160
- Upside to price target
- 49%
- Quarterly earnings growth
- -0.2%
- Revenue growth
- 2.9%
- Forward EPS
- 7.39
- Trailing EPS
- 5.97
- Analyst moves in the last 60 days
- 6
- Strong buy: 3
- Buy: 8
- Hold: 8
- Sell: 0
- Strong sell: 0
- Strong buy
- 3
- Buy
- 8
- Hold
- 8
- Sell
- 0
- Strong sell
- 0
- July 27, 2026 · UBS: Maintains rating (Neutral → Neutral)
- July 22, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- July 6, 2026 · HSBC: Maintains rating (Buy → Buy)
- July 1, 2026 · Barclays: Maintains rating (Equal-Weight → Equal-Weight)
- June 30, 2026 · TD Cowen: Maintains rating (Buy → Buy)
- June 26, 2026 · Stifel: Maintains rating (Hold → Hold)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (7)
- UBS Maintains Neutral on Zoetis, Lowers Price Target to $85 (opens in a new tab) — Benzinga
- Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $99 (opens in a new tab) — Benzinga
- Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis (opens in a new tab) — Benzinga
- Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia (opens in a new tab) — Benzinga
- ACCC Subjects Zoetis' Acquisition Of Neogen Genomics Business To Phase 2 Review Over Competition Concerns (opens in a new tab) — Benzinga
- Zoetis Inks Agreement To Acquire Veterinary Teleradiology Services Platform VitalRADS; Financial Terms Undisclosed (opens in a new tab) — Benzinga
- Zoetis Announces EC Grants Marketing Authorization For Poulvac Procerta HVT-ND, Recombinant Vector Vaccine For Protection Of Chickens Against Newcastle Disease And Marek’s Disease Viruses (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 74.4
- Average true range (ATR)
- 3.2%
- Distance to 52-week high
- -51.6%
- 14-day change (14d)
- +0.3%
- 30-day change (30d)
- -1.3%
- 30-day relative strength
- -3.8%
- SPY change (30d)
- +2.5%
- Nearest support
- 74.22
- Distance to nearest support
- 0.2%
- Nearest resistance
- 74.64
- Distance to nearest resistance
- 0.3%
- Volume accumulation ratio (14d / 46d)
- 0.79
- Mid: 74.22 (0.2% away, 0.07 ATR, 12 touches)
- Mid: 73.63 (1% away, 0.32 ATR, 18 touches)
- Mid: 73.02 (1.9% away, 0.58 ATR, 13 touches)
- Mid: 74.64 (0.3% away, 0.1 ATR, 13 touches)
- Mid: 75.61 (1.6% away, 0.5 ATR, 25 touches)
- Mid: 76.01 (2.2% away, 0.67 ATR, 13 touches)
Trends
Evidence
- Average earnings surprise
- +3.5%
- May 7, 2026: actual EPS 1.53 vs estimate 1.62 (surprise -5.3%)
- February 12, 2026: actual EPS 1.48 vs estimate 1.4 (surprise +5.5%)
- November 4, 2025: actual EPS 1.7 vs estimate 1.62 (surprise +4.8%)
- August 5, 2025: actual EPS 1.76 vs estimate 1.61 (surprise +9.2%)
Expected move
- Implied move
- +3.9%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 5%
- 75th percentile move
- 6.1%
- 90th percentile move
- 11.2%
- Up / down moves
- 8 / 12
- Average up move
- +4.0%
- Average down move
- -6.7%
Monitoring and close
What Zoetis Inc. reported
- Status
- Finished
| Actual EPS | 1.87 |
|---|---|
| EPS estimate | 1.86 |
| EPS surprise | +0.5% |
| Revenue | $2,468 million |
| Revenue estimate | $2,502 million |
| Revenue surprise | -1.4% |
Zoetis beat Q2 earnings estimates but missed revenue and cut its 2026 outlook. The outlook remains pessimistic after the guidance reduction.
Sources (16)
- Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds (opens in a new tab) — Benzinga
- William Blair Downgrades Zoetis to Market Perform (opens in a new tab) — Benzinga
- Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut (opens in a new tab) — Yahoo
- Here's What Key Metrics Tell Us About Zoetis (ZTS) Q2 Earnings (opens in a new tab) — Zacks
- Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations (opens in a new tab) — StockStory
- Zoetis Inc. (ZTS) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Zoetis (ZTS) Surpasses Q2 Earnings Estimates (opens in a new tab) — Zacks
- Zoetis cuts annual forecasts as pet healthcare demand slows (opens in a new tab) — Reuters
- Zoetis Announces Appointment Of Jay Saccaro As CFO And COO Effective August 17 (opens in a new tab) — Benzinga
- Zoetis Inc. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
- Zoetis Lowers FY2026 GAAP EPS Guidance from $6.35-$6.50 to $5.55-$5.65 vs $6.43 Est (opens in a new tab) — Benzinga
- Zoetis Lowers FY2026 Adj EPS Guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 Est; Lowers FY2026 Sales Guidance from $9.680B-$9.960B to $9.120B-$9.320B vs $9.726B Est (opens in a new tab) — Benzinga
- Zoetis beat earnings expectations with $1.87 per share, but its sales of $2.468 billion fell short of estimates. — Benzinga
- Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate (opens in a new tab) — Benzinga
- Zoetis Announces Second Quarter 2026 Results (opens in a new tab) — Yahoo
- Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on earnings but not on revenue, and the price is indicating +0.8% pre-market, a move below the stock's usual reaction (about 5%). The figures don't confirm the prior scenario: that move is too small to draw conclusions from.
How the stock reacted
- Outcome
- Partial
- Consolidated
- +3.8%
- Max favorable move (MFE)
- 5.9%
- Max adverse move (MAE)
- 7.2%